An anti-interleukin-6 antibody, tocilizumab, was found to have no significant differences in mortality or clinical outcomes at day 28, but shorter median time to hospital discharge, compared with placebo in a rigorously conducted randomized control trial.
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
cdercder
东方元语
张欢馨
呵呵
OK
aajhajkahna
xing_xing
MozzieMiao
昏睡的蟠桃
Kao
丰富语蕊
yi
可爱的小paper
cat
v0id
yjh123
初景
Nexus
七听
皖公网安备34019202002308
